PERTH, Australia, 31 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to update shareholders on progress made during the December quarter in validating the Company’s platform technology, implementing a new strategic focus, and strengthening both corporate and scientific resources.
Conference Call Details
Shareholders are invited to join a conference being held at 11.30am AEST / 8.30am AWST on Wednesday February 7, hosted by CEO, Stephanie Unwin and CSO, Dr Robert Hayes, to discuss activity during the quarter, followed by Q&A with participants.
For further information please download PDF attached:
Download this document